Gasper J.LaRosa

Partner

New York + 1.212.326.7885

Connect

Share

Gasper LaRosa is a leading pharmaceutical and biotechnology patent lawyer as recognized by clients and his peers. He has more than 20 years of client-focused experience litigating high-profile patent infringement cases involving pharmaceutical products, medical devices, chemical manufacturing processes, and battery technology. He has tried patent cases to juries and to the bench in several federal district courts and the International Trade Commission (ITC). In addition, Gasper has broad experience representing clients as lead counsel in United States Patent and Trademark Office (USPTO) post-grant proceedings.

Gasper's practice focuses particularly on Hatch-Waxman (ANDA), biosimilar (BPCIA), and other patent litigation on behalf of pharmaceutical and biotechnology companies. He has represented major pharmaceutical companies in the enforcement of patents covering some of the world's most successful drug products and drug delivery systems. His representations include litigations and Patent Trial and Appeal Board (PTAB) proceedings concerning biologics (e.g., conjugate vaccines) as well as small molecule blockbuster drugs including, Tagrisso® (treatment of non-small cell lung cancer), OxyContin® (oxycodone hydrochloride extended release tablets), Butrans® (buprenorphine patch, extended release), Androgel ® (transdermal testosterone replacement therapy), Thalomid® (a treatment of multiple myeloma and erythema nodosum leprosum), Revlimid®, Skelaxin® (a muscle relaxant), Avinza® (an extended release morphine sulphate pain reliever), and Univasc® and Uniretic ® (ACE inhibitors).

Gasper is a member of the American Bar Association, the PTAB Bar Association, the Federal Circuit Bar Association, the New York Intellectual Property Law Association, and the American Institute of Chemical Engineers.

Erfahrung

  • Pharmaceutical company wins $107.5 million jury verdict in patent dispute involving AstraZeneca's lung cancer treatment Tagrisso®Jones Day on behalf of a pharmaceutical company won a jury award of $107.5 million in damages after a five-day trial and less than three hours of jury deliberation.
  • Purdue Pharma defends petition for post-grant review of patent against Collegium Pharmaceutical Inc.Jones Day represented patent owner Purdue Pharma L.P. in a post-grant review (PGR) proceeding brought by petitioner Collegium Pharmaceutical Inc. relating to a patent directed to a pharmaceutical formulation containing gelling agent.
  • Purdue Pharma asserts patent infringement claims under Hatch-Waxman Act related to OxyContin® against Accord HealthcareJones Day represents plaintiffs Purdue Pharma L.P. and Purdue Pharmaceuticals L.P. ("Purdue") in a patent litigation under the Hatch-Waxman Act in the District of Delaware.
  • Purdue Pharma asserts patent infringement claims under Hatch-Waxman Act related to extended-release oxycodone analgesic productsJones Day represents plaintiffs Purdue Pharma L.P., Purdue Pharmaceuticals L.P. and Rhodes Technologies in a Hatch-Waxman pharmaceutical patent litigation in the District of New Jersey.
  • Purdue Pharma asserts patent infringement claims under Hatch-Waxman Act related to OxyContin® against Accord HealthcareJones Day represents Purdue Pharma L.P. in asserting patent infringement claims under the Hatch-Waxman Act against generic-drug company Accord Healthcare, Inc. involving several patents directed to OxyContin®.
  • Puma Biotechnology asserts patent infringement claims under Hatch-Waxman Act related to Nerlynx® against SandozJones Day is representing Puma Biotechnology, Inc. in a Hatch-Waxman patent infringement action against Sandoz relating to Sandoz's submission of an Abbreviated New Drug Application to the FDA seeking approval of a purported generic version of Nerlynx® (neratinib) tablets.
  • Purdue enforces formulation and compound patents against Collegium Pharmaceutical's Xtampza® ER extended-release oxycodone capsulesJones Day is representing Purdue Pharma L.P. in a Hatch-Waxman patent infringement action against Collegium Pharmaceutical, Inc., relating to Collegium's submission of a Section 505(b)(2) application for its Xtampza® ER extended-release oxycodone capsules.
  • SK Innovation defeats request to exclude lithium-ion battery technology in ITC dispute with LG ChemJones Day clients SK Innovation Co., Ltd. and SK Battery America, Inc., following an evidentiary hearing in December 2020, prevailed against LG Chem et al. in a patent infringement dispute before the International Trade Commission (ITC) involving lithium-ion battery technology used in electric vehicles.
  • Celgene acquired by Bristol-Myers Squibb for approximately $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.
  • Shiseido acquires Drunk Elephant™ for $845 millionJones Day advised Shiseido Americas Corporation in its $845 million acquisition of Drunk Elephant™.
  • Purdue Pharma asserts patent infringement claims under Hatch-Waxman Act related to OxyContin® against IntellipharmaceuticsJones Day is representing Purdue Pharma L.P. in a Hatch-Waxman patent infringement action against defendants, relating to the defendants' submission of a Section 505(b)(2) New Drug Application to the FDA seeking approval of an extended-release oxycodone formulation.
  • Purdue Pharma successfully resolves Hatch-Waxman patent infringement claims against Ascent related to OxyContin®Jones Day successfully represented Purdue Pharma L.P. in related Hatch-Waxman patent infringement actions against defendant Ascent Pharmaceuticals, Inc., pertaining to the submission of an Abbreviated New Drug Application to the FDA seeking approval of a generic version of OxyContin®.
  • Purdue Pharma successfully moves for additional discovery regarding real-party-in-interest, leading to termination of IPRs before institutionJones Day defended patent owner, Purdue Pharma L.P., in connection with two inter partes review (IPR) petitions brought by the petitioner, Kashiv Pharma, LLC, against U.S. Patent Nos. 9,492,392 and 9,492,393.
  • Purdue Pharma successfully resolves Hatch-Waxman patent infringement claims against Epic Pharma related to OxyContin®Jones Day successfully represented Purdue Pharma L.P. in related Hatch-Waxman patent infringement actions against defendants Epic Pharma, LLC and PuraCap Pharmaceutical LLC, pertaining to the submission of an Abbreviated New Drug Application to the FDA seeking approval of a generic version of OxyContin®.
  • Purdue Pharma successfully resolves Hatch-Waxman claims against companies seeking to make generic version of transdermal patch Butrans®Jones Day client Purdue Pharma L.P. successfully resolved a patent infringement action it brought under the Hatch-Waxman Act against two companies that sought FDA approval to market a generic version of Purdue's Butrans® product prior to the expiration of certain patents owned by Purdue.
  • Celgene wins in district court case, invalidating patent asserted against its Thalomid® and Revlimid® brand cancer drugsJones Day successfully defended Celgene Corporation in a patent infringement case brought in the United States District Court for the District of Delaware by Andrulis Pharmaceuticals Corporation, which alleged that Celgene's THALOMID® and REVLIMID® brand cancer drugs infringed U.S. Patent No. 6,140,346 ("'346 patent").
  • AbbVie subsidiary asserts patent infringement claims under Hatch-Waxman Act related to AndroGel® against Perrigo and WatsonJones Day represented Unimed Pharmaceuticals, LLC, a subsidiary of AbbVie, Inc., in a consolidated Hatch-Waxman patent infringement action against Perrigo Company and Watson Laboratories, Inc., relating to the defendants' submission of Abbreviated New Drug Applications to the FDA seeking approval of generic versions of AndroGel® 1.62%, a widely-prescribed treatment for males with low testosterone levels.
  • Purdue Pharma pursues patent infringement suit involving OxyContin(R) against generic drug maker TevaJones Day represents Purdue Pharma L.P., The P.F. Laboratories, Inc., and Purdue Pharmaceuticals L.P. in a Hatch-Waxman Act patent infringement litigation matter relating to Teva Pharmaceuticals USA, Inc.'s attempt to market a generic version of Purdue's controlled-release OxyContin(R) pain relief medication.
  • Schwarz Pharma defends against claims of patent infringement involving omeprazoleJones Day successfully defended Schwarz Pharma, Inc. and other defendants against claims of patent infringement relating to omeprazole, which is used to treat ulcers and gastric reflux disease and is one of the most widely prescribed drugs.
  • Purdue Pharma defends against claims of patent infringementJones Day represents Purdue Pharma L.P., The P.F. Laboratories, Inc., and Purdue Pharmaceuticals L.P. in a patent infringement litigation brought by plaintiff Depomed, Inc., based on Purdue's manufacture and sale of its own patented controlled-release OxyContin(R) pain relief medication.
    •

    July 2024 Commentary

    Federal Circuit Revives Induced Infringement Claims Despite "Skinny Label" Carve-Out

    January 2022 Commentary

    Inducement Suit Proceeds Against Insurance Company for Encouraging Use of Generic Drug

    September 2021 Commentary

    Federal Circuit Vacates Judgment, Reinstates Jury's Verdict of Induced Infringement

    JUNE 2020 Alert

    FDA Launches Review of Orange Book Patent Listing Practices

    December 2019 Blog

    PTAB Bar Association – Thought Leader Summit Recap, PTAB Litigation Blog

    October 2019 Blog

    Trial Court Denies Amendment of Contentions To Add Reexam Claims Following Successful IPR, PTAB Litigation Blog

    June 2019 Commentary

    Lead Compound Analysis Not Applicable to Certain Method-of-Treatment Claims

    May 2019 Blog

    Precedential: PTAB Considers § 314(a) Factors Even When Denying Under § 325(d), PTAB Litigation Blog

    August 2018 Blog

    PTAB Grants Rare Motion for Additional Discovery, PTAB Litigation Blog

    July 2018 Blog

    Chief Judge Ruschke Presents on PTAB Fact v. Myth, PTAB Litigation Blog
    Weitere Veröffentlichungen

    • March 24, 2020
      American Conference Institute's 35th FDA Boot Camp
    • March 26, 2019
      Hatch-Waxman and BPCIA Fundamentals: Understanding Follow-On Products and the Rules for Generic Entry, FDA Boot Camp
    • November 29, 2018
      Privity at the PTAB since RPX
    • June 20, 2017
      Preparing for Litigation Before Litigation, 36th Global Litigation Confex
    • October 27, 2015
      Global Legal ConfEx - IP LItigation Around the World
    • September 18, 2014
      The Food and Drug Law Institute - Celebrating the 30th Anniversary of the Hatch-Waxman Amendments: The Past, Present and Future of Generic Drugs
    • August 1, 2013
      Successfully Navigating FDA Citizen Petitions and Responses
    • May 7, 2010
      Foreign Exchange: The Impact and Role of Foreign Forums on U.S. Litigation, AIPLA 2010 Spring Meeting

    Bitte beachten Sie vor dem Versenden:

    Die Informationen auf unserer Website sind für den allgemeinen Gebrauch und stellen keine Rechtsberatung dar. Der Versand dieser E-Mail ist nicht dazu bestimmt, ein Mandatsverhältnis zu begründen, und der Erhalt dieser E-Mail stellt kein Mandatsverhältnis dar. Alles, was Sie an jemanden in unserer Kanzlei senden, ist nicht vertraulich oder privilegiert, es sei denn, wir haben zugestimmt, Sie zu vertreten. Wenn Sie diese E-Mail versenden, bestätigen Sie, dass Sie diesen Hinweis gelesen und verstanden haben.